This week’s FDA Matters column, entitled “FDA is Built on Predictability and Expertise, Not Norm-Breaking,” can be found here.
My position has been “whatever you think of the specific policies and actions that Commissioner Makary is pursuing, and 2/ whatever you think of his leadership and management styles….we must speak our truth AND YET also make clear that we support his leadership of FDA.”
Unfortunately, the situation at FDA has deteriorated over the last few weeks. The downside risk has increased greatly. To understand why, please read my column here.
——-
FDA Matters analyzes FDA policy and regulatory issues and advocates for a more effective, efficient, and fair FDA.
FDA Matters doesn’t cover the news….we provide analysis of what’s behind the news.
If you would like to subscribe (free), you can do so on our website (www.fdamatters.com) or by sending a note to sgrossman@fdamatters.com. We recognize that you are busy, so we limit our content to 1-2 columns per week and ensure it is always a 5-minute read or less.
